Sinopharm Group Co (FRA:X2S) Net Income From Continuing Operations : €1,813 Mil (TTM As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Sinopharm Group Co's net income from continuing operations for the six months ended in Dec. 2024 was €840 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2024 was €1,813 Mil.

Sinopharm Group Co Net Income From Continuing Operations Historical Data

The historical data trend for Sinopharm Group Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co Net Income From Continuing Operations Chart

Sinopharm Group Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

Get a 7-Day Free Trial

1,960.70

2,362.55

2,513.63

2,505.90

1,836.48

Sinopharm Group Co Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Net Income From Continuing Operations	Get a 7-Day Free Trial															1,429.89	1,142.70	1,367.26	972.77	840.06

Sinopharm Group Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €1,813 Mil.

Sinopharm Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (FRA:X2S) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

SHTDY:USA SHTDF:USA 01099:Hong Kong X2S:Germany

Address

No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023

Website

http://www.sinopharmgroup.com.cn

Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.

Sinopharm Group Co Headlines

No Headlines